Form 4: Acurx Pharmaceuticals Director Robert J. DeLuccia Granted Stock Options

Robert J. DeLuccia, a director and 10% owner of Acurx Pharmaceuticals, was granted stock options to purchase 250,000 shares of the company's common stock on February 23, 2024.

Summary

• Robert J. DeLuccia, a director and 10% owner of Acurx Pharmaceuticals, filed a Form 4 on April 3, 2024, reporting a transaction.
• On February 23, 2024, DeLuccia was granted stock options to purchase 250,000 shares of Acurx Pharmaceuticals' common stock at an exercise price of $3.15.
• The options vest in 36 equal monthly installments starting on the grant date and expire on February 22, 2034.
• The filing indicates that the transaction was reported late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The granting of stock options is generally positive, but the late filing introduces a minor negative aspect.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.

Negatives

• The late filing of the Form 4 indicates a lapse in administrative oversight, although it was attributed to an inadvertent error.

Risks

• While the late filing was attributed to an administrative error, repeated instances could raise concerns about internal controls.

Management Comments

• The late filing was due to an inadvertent administrative error and not any error of the Reporting Person.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across the pharmaceutical industry.
• The vesting schedule of 36 months is also fairly typical.
• Comparing the size of the grant (250,000 shares) to similar companies would require analyzing their executive compensation packages and market capitalization.

Stakeholder Impact

• The granting of stock options could potentially incentivize the director to work towards increasing shareholder value.
• The late filing, while minor, could raise concerns among shareholders about the company's internal controls.

Key Dates